There are currently 446 clinical trials in Buffalo, New York looking for participants to engage in research studies. Trials are conducted at various facilities, including Roswell Park Cancer Institute, University of Buffalo, Roswell Park Comprehensive Cancer Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The Effects of an Acute High-intensity Exercise on Heart and Brain Function in People with Spinal Cord Injury
NCT06274658
Recruiting
The heart and brain are regulated by the autonomic nervous system. Control of these organs can be disrupted in people with spinal cord injury (SCI). This may affect their ability to regulate blood pressure during daily activities and process the high-level information. Previous studies show that high-intensity exercise induces better outcomes on heart and information processing ability in non-injured people compared to moderate-intensity exercise. However, it is unknown the effects of high-inten... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/03/2025
Locations: University at Buffalo, South Campus, Buffalo, New York
Conditions: Autonomic Nervous System Disease, Spinal Cord Injuries, Cognition
Register for Updates
Amplatzer Amulet LAAO Vs. NOAC
NCT04226547
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Buffalo General Hospital, Buffalo, New York
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy
NCT05359848
Recruiting
Caloric restriction may alter the response to chemotherapy induced stress response and enhance its antitumor effect. This study intends to use an intermitted caloric restriction protocol with alternate days before the chemotherapy administration to enhance the cytotoxic effect generated by standard treatment of cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: University at Buffalo / Great Lakes Cancer Care, Buffalo, New York +1 locations
Conditions: Medical Oncology, Integrative Oncology, Medical Nutrition Therapy
Register for Updates
Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
NCT06172283
Recruiting
This is a a pilot study to assess the feasibility of intermittent caloric restriction (plus a plant-enriched diet optionally) in prostate cancer patients receiving androgen deprivation therapy. Study feasibility measures will include enrollment rate, drop-out rate and compliance with diet measured by self-reports.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: University at Buffalo/Great Lakes Cancer Center, Buffalo, New York
Conditions: Prostate Cancer
Register for Updates
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC
NCT06222593
Recruiting
This is a Phase I/II open-label, efficacy and safety study of bicalutamide in combination with sunitinib in patients with advanced renal cell carcinoma (RCC) who have been treated with a receptor tyrosine kinase inhibitor (RTKI) and experienced disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: UB/ Great Lakes Cancer Care, Buffalo, New York
Conditions: Carcinoma, Renal Cell
Register for Updates
Pharmacist-Led SDoH Screening Intervention During Transitions of Care in an Acute Care Setting
NCT06802393
Recruiting
The study is a quasi-experimental pilot study conducted at Buffalo General Medical Center (BGMC). It aims to evaluate the feasibility, acceptability, and effectiveness of a pharmacist-led intervention addressing health-related social needs (HRSN) during transitions of care in the emergency department. The intervention involves: 1) pharmacist led medication review, 2) screening patients using the Accountable Health Communities (AHC) HRSN tool, connecting them to local community-based organization... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Buffalo General Medical Center, Buffalo, New York
Conditions: Health Related Social Needs (HRSN), Pharmacy, Medication Reconciliation
Register for Updates
Krabbe Disease Global Patient Registry
NCT02993796
Recruiting
The purpose of this study is to develop a clinical database of individuals diagnosed with Krabbe disease in order to determine which symptoms herald the onset of clinical disease in the various phenotypes of Krabbe disease; to determine whether level of GALC enzyme activity, or a specific genetic mutation predict the clinical course; and to determine which neurodiagnostic tests predict onset and/or severity of the disease.
Gender:
ALL
Ages:
All
Trial Updated:
02/07/2025
Locations: State University of New York at Buffalo, Buffalo, New York
Conditions: Krabbe Disease
Register for Updates
Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance
NCT06733350
Recruiting
This phase IV trial studies the effects of testosterone replacement therapy (TRT) on treatment outcomes in hypogonadal men with prostate cancer that has not spread to other parts of the body (localized) and who are on active surveillance (AS). AS in prostate cancer involves closely watching the patient's condition through regular physical exams and blood tests, but not giving treatment unless there are changes in test results. It can be a practical alternative to treatment in localized prostate... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Register for Updates
Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A
NCT05248594
Recruiting
We have developed a questionnaire to elucidate the dosing, frequency and indication for the use of emicizumab in patients with Hemophilia A (mild, moderate or severe) ages 0-3 years. We are also collecting data on any pre-, peri and post surgical practices while on emicizumab. More importantly, we are asking if pediatricians are planning to introduce factor 8 to children who are already on emicizumab for primary prophylaxis as well as how and when they are planning to do so. We hope that this da... Read More
Gender:
ALL
Ages:
36 months and below
Trial Updated:
01/31/2025
Locations: Western NY Blood Care - Research Foundation for SUNY, Buffalo, New York
Conditions: Hemophilia A
Register for Updates
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677
Recruiting
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Register for Updates
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
NCT04269213
Recruiting
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
01/30/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Register for Updates
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
NCT05274048
Recruiting
This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation design in patients with metastatic or unresectable gastro-esophageal cancer that are HER2-overexpressing (IHC 3+ or IHC2+/ISH+) and any other gastrointestinal cancer with HER2 expression with IHC3+. Patients must have progressed or been intolerant of at least one prior line... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation
Register for Updates